Side-by-side comparison of AI visibility scores, market position, and capabilities
Cambridge biotech developing small molecules targeting "undruggable" transcription factors for FSHD and cancer; YC W20 $6.71M competing with Fulcrum Therapeutics in the rare muscle disease therapeutic space.
Altay Therapeutics is a Cambridge, Massachusetts-based biotechnology company — backed by Y Combinator (W20) with $6.71 million raised including a $3 million seed round — developing first-in-class small molecule therapeutics that target transcription factors, historically considered "undruggable" proteins due to their lack of conventional binding sites, for rare genetic diseases and oncology indications. Founded in 2019, Altay's lead programs focus on facioscapulohumeral muscular dystrophy (FSHD) — a rare, progressive muscle disease affecting 1 in 8,500 people with no approved treatments — and cancer targets where transcription factor dysregulation drives tumor growth.
$2.3B raised at $29.3B valuation; $2B+ ARR (Q1 2026); used by 50%+ of Fortune 500. Dominant commercial AI coding tool; built on VSCode fork with native agent mode. Competing with GitHub Copilot, Windsurf, and Lovable in the vibe-coding wave.
Cursor is an AI-powered code editor built on Visual Studio Code that integrates advanced language models to provide intelligent code completion, generation, debugging, and refactoring capabilities directly in the development workflow. The company serves software developers seeking to accelerate coding productivity through AI assistance while maintaining full control and understanding of their code. Cursor delivers value through contextual code suggestions that understand entire codebases, natural language commands to modify code, inline AI chat for explaining complex code, and a familiar VS Code interface that requires minimal learning curve for existing developers.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.